Publications
Detailed Information
MYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Kyoung Un | - |
dc.contributor.author | Lee, Hee Eun | - |
dc.contributor.author | Park, Do Joong | - |
dc.contributor.author | Jung, Eun Ji | - |
dc.contributor.author | Kim, Hyung-Ho | - |
dc.contributor.author | Kim, Woo Ho | - |
dc.contributor.author | Lee, Hye Seung | - |
dc.contributor.author | Choe, Gheeyoung | - |
dc.contributor.author | Song, Junghan | - |
dc.date.accessioned | 2012-05-31T08:18:31Z | - |
dc.date.available | 2012-05-31T08:18:31Z | - |
dc.date.issued | 2009-05 | - |
dc.identifier.citation | CLINICAL CHEMISTRY AND LABORATORY MEDICINE; Vol.47 5; 530-536 | ko_KR |
dc.identifier.issn | 1434-6621 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76706 | - |
dc.description.abstract | Background: Detection of tumor-associated genetic alterations in plasma of cancer patients has recently been suggested to be an accurate method for detecting early or recurrent cancer. Methods: We performed quantitative real-time PCR for MYC and GAPDH in tissue and plasma samples of 57 patients with gastric cancer and in plasma of 79 cancer-free individuals. We also performed two-color MYC fluorescence in situ hybridization (FISH) in tissue from the 57 patients with gastric cancer. Results: The tissue MYC/GAPDH ratio by real-time PCR was significantly correlated with MYC status by FISH (p<0.001). The mean ratio of plasma MYC/GAPDH was 5.226+/-3.578 (range: 1.25-18.35) in gastric cancer patients, and 2.436+/-0.881 (range: 1.00-5.00) in the healthy volunteers (p<0.001). We used receiver-operating characteristics (ROC) curve analysis to select two optimal plasma MYC/GAPDH cut-offs of 2.725 and 5.225. The sensitivity and specificity were 75.4% and 76.9% at 2.725, 38.6% and 100% at 5.225, respectively. The plasma MYC/GAPDH ratio from cancer patients was significantly correlated with the tissue MYC/GAPDH ratio (p=0.009), and tissue MYC status by FISH (p=0.024). Conclusions: These findings suggest that the plasma MYC/GAPDH ratio, as determined by real-time PCR, may be an alternative non-invasive approach for detecting gastric cancer. Clin Chem Lab Med 2009; 47:530-6. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WALTER DE GRUYTER & CO | ko_KR |
dc.subject | MYC | ko_KR |
dc.subject | plasma DNA | ko_KR |
dc.subject | stomach cancer | ko_KR |
dc.subject | real-time PCR | ko_KR |
dc.title | MYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 박경운 | - |
dc.contributor.AlternativeAuthor | 이희은 | - |
dc.contributor.AlternativeAuthor | 박도중 | - |
dc.contributor.AlternativeAuthor | 정은지 | - |
dc.contributor.AlternativeAuthor | 송정한 | - |
dc.contributor.AlternativeAuthor | 김형호 | - |
dc.contributor.AlternativeAuthor | 최기영 | - |
dc.contributor.AlternativeAuthor | 김우호 | - |
dc.contributor.AlternativeAuthor | 이혜승 | - |
dc.identifier.doi | 10.1515/CCLM.2009.126 | - |
dc.citation.journaltitle | CLINICAL CHEMISTRY AND LABORATORY MEDICINE | - |
dc.description.citedreference | Kim MA, 2007, HUM PATHOL, V38, P1386, DOI 10.1016/j.humpath.2007.02.005 | - |
dc.description.citedreference | Sai S, 2007, ANTICANCER RES, V27, P2747 | - |
dc.description.citedreference | Mitsui F, 2007, MODERN PATHOL, V20, P622, DOI 10.1038/modpathol.3800777 | - |
dc.description.citedreference | Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015 | - |
dc.description.citedreference | Corzo C, 2006, CANCER GENET CYTOGEN, V165, P151, DOI 10.1016/j.cancergencyto.2005.08.013 | - |
dc.description.citedreference | Crew KD, 2006, WORLD J GASTROENTERO, V12, P354 | - |
dc.description.citedreference | Calcagno DQ, 2005, ANTICANCER RES, V25, P4069 | - |
dc.description.citedreference | Gotoh T, 2005, J CLIN ONCOL, V23, P5205, DOI 10.1200/JCO.2005.02.014 | - |
dc.description.citedreference | Tse C, 2005, CLIN CHEM, V51, P1093, DOI 10.1373/clinchem.2004.044305 | - |
dc.description.citedreference | Kindich R, 2005, CLIN CHEM, V51, P649, DOI 10.1373/clinchem.2004.045013 | - |
dc.description.citedreference | Lee TL, 2002, CLIN CANCER RES, V8, P1761 | - |
dc.description.citedreference | Usadel H, 2002, CANCER RES, V62, P371 | - |
dc.description.citedreference | *AM JOINT COMM CAN, 2002, AJCC CANC STAG MAN, P99 | - |
dc.description.citedreference | Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262 | - |
dc.description.citedreference | Lee HS, 2001, CANCER, V92, P1427 | - |
dc.description.citedreference | Lo YMD, 2001, CLIN CANCER RES, V7, P1856 | - |
dc.description.citedreference | Koo SH, 2000, CANCER GENET CYTOGEN, V117, P97 | - |
dc.description.citedreference | AALTONEN LA, 2000, INT AGENCY RES CANC, P37 | - |
dc.description.citedreference | Castells A, 1999, J CLIN ONCOL, V17, P578 | - |
dc.description.citedreference | Hara T, 1998, LAB INVEST, V78, P1143 | - |
dc.description.citedreference | Landis SH, 1998, CA-CANCER J CLIN, V48, P6 | - |
dc.description.citedreference | Suzuki S, 1997, J SURG ONCOL, V66, P173 | - |
dc.description.citedreference | Nawroz H, 1996, NAT MED, V2, P1035 | - |
dc.description.citedreference | Henriksson M, 1996, ADV CANCER RES, V68, P109 | - |
dc.description.citedreference | PARK JG, 1990, CANCER RES, V50, P2773 | - |
dc.description.citedreference | STROUN M, 1989, ONCOLOGY, V46, P318 | - |
dc.description.citedreference | LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31 | - |
dc.description.tc | 3 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.